Filing Flows › Health Care › Edap TMS SA (FOCL)
Edap TMS SA (FOCL) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Edap TMS SA (FOCL) Q3 2026 earnings results →
Q3 2026 Revenue up 26% year over year to $9.8M · 45¢ of every $1 of revenue lost · operating margin -79.1%
Edap TMS SA made $9.8M in Q3 2026 (+26% Y/Y): Goods $6.5M, RPPs & leases $2.4M, Spare parts and services $972K. Operating margin -79.1%, net loss $4.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $9.8M in Q3 2026, up 26% year over year and down 26% from the previous quarter. Goods was the largest line at 66% of revenue. Goods added $1.6M year over year (up 33%), 80% of the total change.
Gross margin was 51.4%, up 4.8 points from a year earlier. Operating costs exceeded revenue by $7.8M, an operating margin of -79.1%. Operating expenses grew 24% against revenue growth of 26%. The fastest-growing cost line was Sales & marketing (+41%). The quarter ended with a net loss of $4.5M, narrower than the previous quarter's $14.5M loss. Non-operating items added $3.3M, -75% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$4.0M. Non-cash charges added back $1.0M of depreciation and amortization. Working capital and other items used $560K. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$5.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $9.8M | +26% | -79.1% | −$4.5M | −$4.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Edap TMS SA
EDAP TMS S.A. (“EDAP,” the “Company,” “we,” “us,” or “our”) is a medical technology company focused on the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices. Our legal name is EDAP TMS S.A., and our commercial name is Focal One ® . We were founded in 1979 as a société anonyme organized under the laws of France for a duration of 60 years from the date of incorporation, unless extended by shareholder approval in accordance with French corporate law. We are headquartered in Vaulx-en-Velin, France and operate in the United States, Europe, Asia and the rest of the world. We are listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “EDAP.”
In its own words, from its 10-K, filed Mar 25, 2026.
Edap TMS SA against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +26% against the peers' median +14%. Operating margin: -79.1% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| FOCL Edap TMS SA | Q3 2026 | $9.8M | +26% | -79.1% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: Edap TMS SA 10-Q on SEC EDGAR · CIK 1041934 · Electromedical & Electrotherapeutic Apparatus
Guidance and outlook
13F: who owns FOCL and who is buying
More on FOCL
History
Every quarter: Q3 2026 results